BioNTech vs. Vertex Pharmaceuticals: Which Healthcare Stock Is a Better Buy for 2027?
Vertex Pharmaceuticals earns steady profits from its cystic fibrosis medicines while expanding into new diseases. BioNTech has a large cash cushion and a growing cancer pipeline, but its COVID vaccine sales are fading.
Full story
Read the full story at The Motley Fool ↗
Continue reading this story on The Motley Fool, the publisher that reported it.
AI tools
Written by AI from the article text. It can make mistakes; check the original story.
